Please ensure Javascript is enabled for purposes of website accessibility

Here's Why the Best Is Yet to Come for Exelixis, Inc.

By Brian Orelli, PhD - Apr 20, 2017 at 1:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's more upside left in this biotech.

Exelixis (EXEL 1.30%) has been on a tear over the last year, nearly quadrupling.

EXEL Chart

EXEL data by YCharts.

While much of the growth in Exelixis' stock price has to do with the better-than-expected launch of Cabometyx in kidney cancer, the biotech still has room to run.

Expanding sales

Beyond the second-line indication that Cabometyx is currently approved for, Exelixis is looking to gain approval from the Food and Drug Administration (FDA) to market the drug for newly diagnosed patients with advanced kidney cancer. Arguably some of those potential sales are already priced into the current valuation, but an FDA approval isn't guaranteed -- the biotech is seeking marketing approval based on a phase 2 trial -- so there should be a bump in the valuation if Cabometyx gains FDA approval for the first-line indication.

Exelixis is also testing Cabometyx as a treatment for liver cancer. The next interim look at the data from the phase 3 trial, dubbed CELESTIAL, is expected this year. If the drug isn't statistically better than placebo, Exelixis will get one more chance to prove the drug helps patients when the trial reads out its complete data at a later, undisclosed, point.

Beyond those near-term opportunities, Exelixis is testing Cabometyx in combination with other drugs including Bristol-Myers Squibb's (BMY 1.49%) Opdivo and Roche's Tecentriq. Through collaborations with Bristol-Myers and Roche, Exelixis recently announced plans to run phase 3 trials based on promising phase 2 data for the combinations.

Those other drugs

Most investors are focused on Cabometyx -- for good reason -- but Exelixis does benefit financially from other drugs as well.

A partnership with Genentech, which was purchased by Roche, led to the development of Cotellic, which was approved to treat skin cancer in 2015. Roche and Exelixis share profits and losses on the sales of Cotellic, which is expected to turn a profit this year. But the bigger opportunity for Cotellic will likely come from combination therapies with other drugs. In the last year or so, Roche has started three new phase 3 trials testing Cotellic in different settings. Interestingly, Bristol-Myers Squibb has also tested Cotellic with Opdivo, supporting the idea that combinations are likely to spur future growth in sales of Cotellic.

Exelixis also has a late-stage drug out-licensed to Daiichi Sankyo. It goes by the codename CS-3150 and started a phase 3 trial in patients with high blood pressure last year. Daiichi Sankyo is responsible for development, so at this point, Exelixis just needs to sit back and see if it can collect more milestone payments and double-digit royalties on sales if the drug is eventually approved.

Scientist in a laboratory

Image source: Getty Images.

Wild cards

There are a couple of other outcomes that could spur a stock-price increase, although it's arguably harder to predict whether any of these will come to fruition:

  • Buyout -- certainly not the best investment thesis, but a real possibility given large pharma's desire to buy growth. Call it potential upside that really shouldn't be factored into the valuation.
  • Rebuilding pipeline -- management has expressed interest in restarting Exelixis' drug discovery after shutting it down to save cash. It's a longer-term scenario, but at least it should offer some potential future growth if a buyout doesn't happen.
  • Acquisition -- a second approved drug could help Exelixis leverage its sales force. The company doesn't have a whole lot of free cash to make a large purchase, but it might be possible to do a transaction for stock if the right deal presented itself.

Multiple ways

It's hard to call Exelixis cheap, but with multiple ways at its disposal to increase its value, investors should consider taking at least a small piece of this biotech with potential for better things to come.

Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Exelixis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$19.48 (1.30%) $0.25
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.